Loading…
The patent covers the company's noninvasive lung cancer detection technology.
bioAffinity Technologies, Inc. (Nasdaq: BIAF) received notification that the Japan Patent Office granted a patent for its CyPath® Lung technology and the associated AI-built algorithm. The technology is designed for the noninvasive detection of lung cancer.
The granted patent enhances bioAffinity's intellectual property portfolio, providing protection for its innovative diagnostic approach in the Japanese market. The company currently has 294,799 shares in free float and 600,736 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.